Dr. Omid Hamid is the Chief of Translational Research and Immuno-Oncology at The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, in Los Angeles, California, USA, where he serves as the Co-Director of the Melanoma and Director of Phase I Programs. His areas of expertise include immunotherapy and phase I drug development. He is recognized as one of the pre-eminent immuno-oncologists and melanoma specialists in the world, and has published extensively on and been at the forefront of paradigm-shifting breakthrough treatments, including BRAF/MEK-targeted agents, anti-CTLA4, anti-PD-1 and anti-PD-L1 therapies. His current research interests include next-generation immunotherapeutics, including novel immune-checkpoint inhibitors, bispecific antibodies, adoptive T cell therapies and oncolytic therapies, with a focus on combinatorial approaches.